AstraZeneca: DESTINY-Breast02 Results Confirm Efficacy Seen In Previous Trials Of ENHERTU

AstraZeneca PLC said Enhertu significantly delayed disease progression in DESTINY-Breast02 phase III trial versus physician's choice of treatment in patients with HER2-positive metastatic breast cancer. The trial results confirmed the efficacy and safety profile seen in DESTINY-Breast01 and were consistent with the results seen across the company's broader clinical programme in HER2-positive metastatic breast cancer.

ENHERTU is a specifically engineered HER2 directed antibody drug conjugate being jointly developed and commercialized by Daiichi Sankyo (DSKYF.PK) and AstraZeneca (AZN,AZN.L).

"As this is the confirmatory trial for our current breast cancer indication in Europe and several other countries, we look forward to sharing these findings with regulatory authorities to add to the body of data for Enhertu for the treatment of HER2-positive metastatic breast cancer," said Ken Takeshita, Global Head, R&D, Daiichi Sankyo.

For More Such Health News, visit rttnews.com.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Three experimental physicists - Alain Aspect, John F. Clauser and Anton Zeilinger - have won this year's Nobel Prize for physics for their achievements in quantum mechanics. Announcing the winners in Stockholm Tuesday, the Royal Swedish Academy of Sciences said the coveted prize was awarded to the trio "for experiments with entangled photons, establishing the violation of Bell inequalities and pi The United States has announced that it will be imposing new round of sanctions this week on perpetrators of violence against peaceful protestors in Iran. The United States is also holding accountable Iranian officials and entities such as the Morality Police, that are responsible for employing violence to suppress civil society, President Joe Biden said in a statement. Biden said he is gravel Factory Orders, Job Openings, and Labor Turnover Survey might be the major highlights on Tuesday. Fed speeches also will get attention. Early signs from the U.S. Futures Index suggest that Wall Street might open higher. Asian shares finished broadly up and European shares are progressing. As...
Follow RTT